Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 143, Issue , 2014, Pages 250-258

  Skarydova, Lucie ^a   Hofman, Jakub ^a   Chlebek, Jakub ^b   Havrankova, Jana ^a   Kosanova, Katerina ^a   Skarka, Adam ^a   Hostalkova, Anna ^b   Plucha, Tomas ^a   Cahlikova, Lucie ^b   Wsol, Vladimir ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

AKR1C3; Alkaloids; Cancer; Inhibitor; Isoquinoline; Natural

Indexed keywords

2' HYDROXYFLAVANONE; AKR1C3 INHIBITOR; ALKALOID; CANADINE; DAUNORUBICIN; FLAVANONE; INDOMETACIN; ISOQUINOLINE ALKALOID; RECOMBINANT ENZYME; STYLOPINE; UNCLASSIFIED DRUG; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN; BERBERINE DERIVATIVE; ENZYME INHIBITOR; TESTOSTERONE;

ARTICLE; CYTOTOXICITY; DRUG ISOLATION; FOLLOW UP; HUMAN; HUMAN CELL; IC 50; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG EFFECTS; ENZYMOLOGY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

3-HYDROXYSTEROID DEHYDROGENASES; BERBERINE ALKALOIDS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; TESTOSTERONE; TUMOR CELLS, CULTURED;

EID: 84900462206     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2014.04.005     Document Type: Article

References (53)

1. D.R. Bauman, S. Steckelbroeck, and T.M. Penning The roles of aldo-keto reductases in steroid hormone action Drug News Perspect. 17 2004 563 578 (Pubitemid 40136607)
2. T.M. Penning Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action Hum. Reprod. Update 9 2003 193 205 (Pubitemid 36827058)
3. T.L. Rizner, and T.M. Penning The role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism Steroids 79 2014 49 63
4. T.M. Penning, and M.C. Byrns Steroid hormone transforming aldo-keto reductases and cancer Ann. N. Y. Acad. Sci. 1155 2009 33 42
5. M.C. Byrns, S. Steckelbroeck, and T.M. Penning An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies Biochem. Pharmacol. 75 2008 484 493 (Pubitemid 350298472)
6. A.R.A.H. Hamid, M.F. Pfeiffer, A. Dudek, M. Voller, G.W. Verhaegh, and F.P. Smit et al. AKR1C3 - a potential marker and therapeutic target in castration resistance prostate cancer Eur. Urol. Suppl. 11 2012 E239
7. M.C. Byrns, and T.M. Penning Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs Chem. Biol. Interact. 178 2009 221 227
8. T.M. Penning, S. Steckelbroeck, D.R. Bauman, M.W. Miller, Y. Jin, and D.M. Peehl et al. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors Mol. Cell. Endocrinol. 248 2006 182 191
9. T.L. Rizner, T. Smuc, R. Rupreht, J. Sinkovec, T.M. Penning, and AKR1C1 AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer Mol. Cell. Endocrinol. 248 2006 126 135
10. A.O. Adeniji, M. Chen, and T.M. Penning AKR1C3 as a target in castrate resistant prostate cancer J. Steroid Biochem. Mol. Biol. 137 2013 136 149
11. V.L. Miller, H.K. Lin, P. Murugan, M. Fan, T.M. Penning, and L.S. Brame et al. Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma Int. J Clin. Exp. Pathol. 5 2012 278 289
12. J.T. Azzarello, H.K. Lin, A. Gherezghiher, V. Zakharov, Z. Yu, and B.P. Kropp et al. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor Int. J. Clin. Exp. Pathol. 3 2009 147 155
13. A.L. Park, H.K. Lin, Q. Yang, C.W. Sing, M. Fan, and T.B. Mapstone et al. Differential expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system Int. J. Clin. Exp. Pathol. 3 2010 743 754
14. M.C. Byrns, L. Duan, S.H. Lee, I.A. Blair, and T.M. Penning Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer J. Steroid Biochem. Mol. Biol. 118 2010 177 187
15. K.K. Sharma, A. Lindquist, X.J. Zhou, R.J. Auchus, T.M. Penning, and S. Andersson Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues Mol. Cell. Endocrinol. 248 2006 79 86
16. N. Beranic, S. Gobec, and T.L. Rizner Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3 Chem. Biol. Interact. 191 2011 227 234
17. A.D. Heibein, B. Guo, J.A. Sprowl, D.A. Maclean, and A.M. Parissenti Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization BMC. Cancer 12 2012 381
18. J. Hofman, B. Malcekova, A. Skarka, E. Novotna, and V. Wsol Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3 Toxicol. Appl. Pharm. 2014 (unpublished result)
19. T. Matsunaga, A. Hojo, Y. Yamane, S. Endo, O. El-Kabbani, and A. Hara Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers Chem. Biol. Interact. 202 2013 234 242
20. D.R. Bauman, S.I. Rudnick, L.M. Szewczuk, Y. Jin, S. Gopishetty, and T.M. Penning Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes Mol. Pharmacol. 67 2005 60 68 (Pubitemid 40069966)
21. S. Gobec, P. Brozic, and T.L. Rizner Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents Bioorg. Med. Chem. Lett. 15 2005 5170 5175 (Pubitemid 41463641)
22. A.J. Liedtke, A.O. Adeniji, M. Chen, M.C. Byrns, Y. Jin, and D.W. Christianson et al. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17beta-hydroxysteroid dehydrogenase/ prostaglandin F synthase) in castrate-resistant prostate cancer J. Med. Chem. 56 2013 2429 2446
23. A. Krazeisen, R. Breitling, G. Moller, and J. Adamski Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5 Mol. Cell. Endocrinol. 171 2001 151 162 (Pubitemid 32098209)
24. L. Skarydova, L. Zivna, G. Xiong, E. Maser, and V. Wsol AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids Chem. Biol. Interact. 178 2009 138 144
25. P. Brozic, B. Golob, N. Gomboc, T.L. Rizner, and S. Gobec Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3) Mol. Cell. Endocrinol. 248 2006 233 235
26. S. Endo, T. Matsunaga, A. Kanamori, Y. Otsuji, H. Nagai, and K. Sundaram et al. Selective inhibition of human type-5 17beta-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis J. Nat. Prod. 75 2012 716 721
27. D.M. Heinrich, J.U. Flanagan, S.M. Jamieson, S. Silva, L.J. Rigoreau, and E. Trivier et al. Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3 Eur. J. Med. Chem. 62 2013 738 744
28. M.C. Byrns, Y. Jin, and T.M. Penning Inhibitors of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights J. Steroid Biochem. Mol. Biol. 125 2011 95 104
29. L. Cahlikova, K. Macakova, J. Kunes, M. Kurfurst, L. Opletal, and J. Cvacka et al. Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Eschscholzia californica (Papaveraceae) Nat. Prod. Commun. 5 2010 1035 1038
30. L. Cahlikova, L. Opletal, M. Kurfurst, K. Macakova, A. Kulhankova, and A. Hostalkova Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Chelidonium majus (Papaveraceae) Nat. Prod. Commun. 5 2010 1751 1754
31. J. Chlebek, K. Macakova, L. Cahlikovi, M. Kurfurst, J. Kunes, and L. Opletal Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Corydalis cava (Fumariaceae) Nat. Prod. Commun. 6 2011 607 610
32. E.K. Jeong, S.Y. Lee, S.M. Yu, N.H. Park, H.S. Lee, and Y.H. Yim et al. Identification of structurally diverse alkaloids in Corydalis species by liquid chromatography/electrospray ionization tandem mass spectrometry Rapid Commun. Mass Spectrom. 26 2012 1661 1674
33. R. Marek, O. Humpa, J. Dostal, J. Slavik, and V. Sklenar N-15 NMR study of isoquinoline alkaloids Magn. Reson. Chem. 37 1999 195 202
34. L. Skarydova, R. Tomanova, L. Havlikova, H. Stambergova, P. Solich, and V. Wsol Deeper insight into the reducing biotransformation of bupropion in human liver Drug Metab. Pharmacokinet. 29 2014 177 184
35. i for inhibitors of enzyme activity and ligand binding Nucleic Acids Res. 37 2009 441 445
36. J. Hofman, M. Buncek, R. Haluza, L. Streinz, M. Ledvina, and P. Cigler In vitro transfection mediated by dendrigraft poly(l-lysines): the effect of structure and molecule size Macromol. Biosci. 13 2013 167 176
37. V. Wsol, E. Kvasnickova, B. Szotakova, and I.M. Hais High-performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracine J. Chromatogr. B: Biomed. Appl. 681 1996 169 175 (Pubitemid 26193983)
38. A. Skarka, L. Skarydova, H. Stambergova, and V. Wsol Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase Chem. Biol. Interact. 191 2011 66 74
39. T.M. Penning, M.E. Burczynski, J.M. Jez, C.F. Hung, H.K. Lin, and H. Ma et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones Biochem. J. 351 2000 67 77
40. R. Novotna, V. Wsol, G. Xiong, and E. Maser Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3 Toxicol. Lett. 181 2008 1 6
41. V. Wsol, B. Szotakova, H.J. Martin, and E. Maser Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man Toxicology 238 2007 111 118 (Pubitemid 47239213)
42. T. Takemura, N. Ikezawa, K. Iwasa, and F. Sato Metabolic diversification of benzylisoquinoline alkaloid biosynthesis through the introduction of a branch pathway in Eschscholzia californica Plant Cell Physiol. 51 2010 949 959
43. J.J. Lu, J.L. Bao, X.P. Chen, M. Huang, and Y.T. Wang Alkaloids isolated from natural herbs as the anticancer agents Evid. Based Complement Alternat. Med. 2012 2012 485042
44. S. Suzen, and E. Buyukbingol Recent studies of aldose reductase enzyme inhibition for diabetic complications Curr. Med. Chem. 10 2003 1329 1352 (Pubitemid 36896564)
45. M. Kubo, H. Matsuda, K. Tokuoka, Y. Kobayashi, S. Ma, and T. Tanaka Studies of anti-cataract drugs from natural sources. I. Effects of a methanolic extract and the alkaloidal components from Corydalis tuber on in vitro aldose reductase activity Biol. Pharm. Bull. 17 1994 458 459 (Pubitemid 24155157)
46. N. Ikezawa, K. Iwasa, and F. Sato Molecular cloning and characterization of methylenedioxy bridge-forming enzymes involved in stylopine biosynthesis in Eschscholzia californica FEBS J. 274 2007 1019 1035 (Pubitemid 46204421)
47. N.V. Khodorova, A.L. Shavarda, M. Lequart-Pillon, J.C. Laberche, O.V. Voitsekhovskaja, and M. Boitel-Conti Biosynthesis of benzylisoquinoline alkaloids in Corydalis bracteata: compartmentation and seasonal dynamics Phytochemistry 92 2013 60 70
48. M. Gazvoda, N. Beranic, S. Turk, B. Burja, M. Kocevar, and T.L. Rizner et al. 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17beta-hydroxysteroid dehydrogenase (AKR1C3) Eur. J. Med. Chem. 62 2013 89 97
49. S.I. Jang, B.H. Kim, W.Y. Lee, S.J. An, H.G. Choi, and B.H. Jeon et al. Stylopine from Chelidonium majus inhibits LPS-induced inflammatory mediators in RAW 264.7 cells Arch. Pharm. Res. 27 2004 923 929
50. K.A. Salminen, A. Meyer, L. Jerabkova, L.E. Korhonen, M. Rahnasto, and R.O. Juvonen et al. Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids Phytomedicine 18 2011 533 538
51. M. Kulp, and O. Bragina Capillary electrophoretic study of the synergistic biological effects of alkaloids from Chelidonium majus L. in normal and cancer cells Anal. Bioanal. Chem. 405 2013 3391 3397
52. O.S. Bains, M.J. Karkling, T.A. Grigliatti, R.E. Reid, and K.W. Riggs Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin Drug Metab. Dispos. 37 2009 1107 1114
53. O.S. Bains, T.A. Grigliatti, R.E. Reid, and K.W. Riggs Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin J. Pharmacol. Exp. Ther. 335 2010 533 545